The World Health Organization (WHO) has recently unveiled essential new guidance emphasizing the importance of maintaining opioid agonist maintenance treatment (OAMT) as a critical health service. This initiative aims to provide effective strategies for ensuring continuity of care for individuals dealing with opioid dependence, particularly in the face of potential disruptions to services.
To give you some context, in 2022, approximately 60 million individuals worldwide were reported to be involved in non-medical use of opioids. This category includes drugs like heroin, morphine, codeine, fentanyl, methadone, and tramadol. Alarmingly, the WHO estimates that opioids are linked to a staggering number of drug-related fatalities, contributing to around 450,000 of the total 600,000 drug-related deaths each year globally. The leading causes of death associated with opioid use include not just overdose, but also infectious diseases such as HIV and viral hepatitis, highlighting the urgent need for effective treatment options.
OAMT has been identified as a highly cost-effective method for treating opioid dependence. It significantly reduces rates of mortality and morbidity, decreases non-medical opioid usage, and lowers the transmission rates of HIV and hepatitis C virus (HCV). Furthermore, this treatment helps diminish risky behaviors, reduce crime, and cut social costs, all while enhancing the overall well-being and retention of patients in treatment.
The WHO advocates for making OAMT widely accessible, ideally at no cost to patients or covered by public health insurance programs. To ensure its effectiveness, the organization stresses the necessity of integrating opioid dependence treatment into existing healthcare systems, supported by robust clinical governance and accountability measures to maintain high standards of care.
In situations where unplanned interruptions to OAMT occur, timely contingency measures are crucial to reduce potential harm. These strategies might include engaging the community in discussions about mitigation efforts, expanding access to naloxone for managing opioid overdoses, reinforcing take-home OAMT programs in response to staffing shortages, increasing psychosocial support, and fostering coordination among multiple stakeholders involved in treatment.
It's important to note that any sudden reduction in OAMT dosages can pose life-threatening risks. Therefore, if withdrawal from opioids becomes necessary, it is vital that individuals receive proper medical guidance according to established protocols for withdrawal management with pharmacological assistance.
The WHO is calling upon countries, service planners, healthcare providers, policymakers, and all relevant stakeholders to prioritize the continuation of these life-saving interventions.
On December 17, the WHO, in collaboration with the International Network on Health and Hepatitis in Substance Users (INHSU) and Médecins du Monde (MdM), will host a global webinar to discuss the implications of this new guidance in more detail.
